Glycosaminoglycans and their sulfate derivatives differentially regulate the viability and gene expression of osteocyte-like cell lines. (September 2014)

• Record Type: Journal Article
• Authors: Tsourdi, Elena; Salbach-Hirsch, Juliane; Rauner, Martina; Rachner, Tilman D; Möller, Stephanie; Schnabelrauch, Matthias; Scharnweber, Dieter; Hofbauer, Lorenz C
• Is Part Of: Journal of bioactive and compatible polymers. Volume 29:Number 5(2014:Sep.)
• Page Start: 474
• Page End: 485
• Publication Date: 2014-09
• Subjects: Extracellular matrix -- bone remodeling -- chondroitin sulfate -- hyaluronan -- osteocyte -- gene delivery -- gene encoding sclerostin -- sulfated glycosaminoglycans -- apoptosis -- osteoprotegerin; Biomedical materials -- Periodicals; Polymers in medicine -- Periodicals; Polymers -- Periodicals; 547.7
• DOI: 10.1177/0883911514546983
• Languages: English
• ISSNs: 0883-9115

Abstract

Collagen and glycosaminoglycans, such as hyaluronan and chondroitin sulfate, are the major components of bone extracellular matrix, and extracellular matrix composites are being evaluated for a wide range of clinical applications. The molecular and cellular effects of native and sulfate-modified glycosaminoglycans on osteocytes were investigated as critical regulators of bone remodeling. The effects of glycosaminoglycans on viability, necrosis, apoptosis, and regulation of gene expression were tested in two osteocyte-like cell lines, the murine MLO-Y4 and the rat UMR 106-01 cells. Glycosaminoglycans were non-toxic and incorporated by osteocytic cells. In MLO-Y4 cells, sulfation of glycosaminoglycans led to a significant inhibition of osteocyte apoptosis, 42% inhibition for highly sulfated chondroitin sulfate and 58% for highly sulfated hyaluronan, respectively. Cell proliferation was not affected. While treatment with highly sulfated chondroitin sulfate increased cell viability by 20% compared to the native chondroitin sulfate. In UMR 106-01 cells, treatment with highly sulfated hyaluronan reduced the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio by 58% compared to the non-sulfated form, whereas highly sulfated chondroitin sulfate led to 60% reduction in the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio in comparison to the native chondroitin sulfate. The expression of SOST, the gene encoding sclerostin, was reduced by 50% and 45% by highly sulfated hyaluronan and chondroitin sulfate, respectively, compared to their native forms. The expression of BMP-2, a marker of osteoblast differentiation, was doubled after treatment with the highly sulfated hyaluronan in comparison to its native form. In conclusion, highly sulfated glycosaminoglycans inhibit osteocyte apoptosis in vitro and promote an osteoblast-supporting gene expression profile.